Cleveland Clinic Abu Dhabi expands clinical trial efforts to address community health issues and enhance medical care in the UAE

Cleveland Clinic Abu Dhabi expands clinical trial efforts to address community health issues and enhance medical care in the UAE

Cleveland Clinic Abu Dhabi explores the application of genome-based research in recent diagnostic studies around obesity and breast cancer The diagnostic studies led by the multidisciplinary research department address major regional diseases and improve overall population health Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi, an M42 company, is setting the benchmark for research by leading groundbreaking observational and interventional studies focused on diagnosis, prevention and therapeutics. Cleveland Clinic Abu Dhabi’s research department, comprising a specialized multidisciplinary research team, has developed several studies that are aimed at reducing the impact of major diseases on community health. The department has over 200 active research studies, out of which 60 were initiated in 2022. The studies on critical topics relating to digestive diseases, neurological and heart ailments, among others, are sometimes undertaken in partnership with various other local and regional institutions. In line with the Department of Health – Abu Dhabi’s drive to improve the overall healthcare of the UAE’s population, the hospital aims to leverage this research as part of its wider efforts to advance treatment options in the UAE and the GCC region in collaboration with other partners and stakeholders in Abu Dhabi. Three studies are currently underway that